Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution

Biomarker discovery produces lists of candidate markers whose presence and level must be subsequently verified in serum or plasma. Verification represents a paradigm shift from unbiased discovery approaches to targeted, hypothesis-driven methods and relies upon specific, quantitative assays optimized for the selective detection of target proteins. Many protein biomarkers of clinical currency are present at or below the nanogram/milliliter range in plasma and have been inaccessible to date by MS-based methods. Using multiple reaction monitoring coupled with stable isotope dilution mass spectrometry, we describe here the development of quantitative, multiplexed assays for six proteins in plasma that achieve limits of quantitation in the 1–10 ng/ml range with percent coefficients of variation from 3 to 15% without immunoaffinity enrichment of either proteins or peptides. Sample processing methods with sufficient throughput, recovery, and reproducibility to enable robust detection and quantitation of candidate biomarker proteins were developed and optimized by addition of exogenous proteins to immunoaffinity depleted plasma from a healthy donor. Quantitative multiple reaction monitoring assays were designed and optimized for signature peptides derived from the test proteins. Based upon calibration curves using known concentrations of spiked protein in plasma, we determined that each target protein had at least one signature peptide with a limit of quantitation in the 1–10 ng/ml range and linearity typically over 2 orders of magnitude in the measurement range of interest. Limits of detection were frequently in the high picogram/milliliter range. of to a with of proteins in plasma by and were by robust processing protein and by at the peptide level to reaction methods here a for quantitative MS-based assays of level proteins in Biomarker discovery produces lists of candidate markers whose presence and level must be subsequently verified in serum or plasma. Verification represents a paradigm shift from unbiased discovery approaches to targeted, hypothesis-driven methods and relies upon specific, quantitative assays optimized for the selective detection of target proteins. Many protein biomarkers of clinical currency are present at or below the nanogram/milliliter range in plasma and have been inaccessible to date by MS-based methods. Using multiple reaction monitoring coupled with stable isotope dilution mass spectrometry, we describe here the development of quantitative, multiplexed assays for six proteins in plasma that achieve limits of quantitation in the 1–10 ng/ml range with percent coefficients of variation from 3 to 15% without immunoaffinity enrichment of either proteins or peptides. Sample processing methods with sufficient throughput, recovery, and reproducibility to enable robust detection and quantitation of candidate biomarker proteins were developed and optimized by addition of exogenous proteins to immunoaffinity depleted plasma from a healthy donor. Quantitative multiple reaction monitoring assays were designed and optimized for signature peptides derived from the test proteins. Based upon calibration curves using known concentrations of spiked protein in plasma, we determined that each target protein had at least one signature peptide with a limit of quantitation in the 1–10 ng/ml range and linearity typically over 2 orders of magnitude in the measurement range of interest. Limits of detection were frequently in the high picogram/milliliter range. of to a with of proteins in plasma by and were by robust processing protein and by at the peptide level to reaction methods here a for quantitative MS-based assays of level proteins in methods have the for discovery of and protein biomarker discovery approaches that high mass and processing a serum by coupled with mass biomarker discovery and the and to clinical of protein and are to proteins that are of proteins and by mass without or spiked for the quantitative of for with of protein quantitation in using isotope by in a and to Quantitative of protein using to lists of discovery in to of candidate biomarkers that must be subsequently verified in plasma biomarker discovery and the and to clinical the of a of are the development and clinical and of plasma and clinical of biomarkers relies of for the target and high the development of a for quantitation of one target protein a development and upon the of high protein with the to to quantitative assays to the candidate discovery and reaction monitoring multiple reaction stable isotope limit of limit of to of stable isotope with by multiple reaction stable isotope limit of limit of to of stable isotope with by coupled with stable isotope dilution using a mass a for quantitative measurement of target proteins. been a for of in clinical of by mass in quantitation a mass MS-based quantitative assays have the for high and of variation of mass are the of and to by with a in a the a of derived from the are mass using the detection limit for peptides by to with unbiased by and monitoring of the of interest. in for the and or measurement of are to a in known a of candidate proteins be and in a of for in in with been to be for of proteins in plasma of peptide for mass of peptides in of peptides in and with and mass of by mass mass of with of proteins and from by of protein in the serum of with using multiple reaction monitoring mass and peptide of proteins in serum by multiple reaction monitoring mass in a of the biomarker in serum by using protein and isotope dilution of proteins by peptides derived by of the target protein signature peptides are quantitative, of the protein are to be in present in proteins in the a stable protein be by the from the exogenous and of signature peptides and or with for peptides to or in the mass range of the mass to peptides in unbiased discovery peptides be from in of the protein MS-based assays be developed for candidate biomarkers from and a for candidate biomarker for detection and quantitation of proteins by to date that without to and proteins at concentrations in plasma of the biomarker in serum by using protein and isotope dilution Quantitative mass multiple reaction monitoring assays for plasma we have and optimized processing and methods to with sufficient throughput, recovery, and reproducibility to enable robust detection and quantitation of candidate biomarker proteins at the nanogram/milliliter in plasma without immunoaffinity enrichment at either the protein or peptide a the for a that enrichment and to the limit of quantitation of assays to the known protein range of plasma. protein and were from from were of or were of immunoaffinity depleted plasma from a healthy donor. immunoaffinity were the high plasma proteins and were depleted using a from using with the and to the high plasma proteins and were depleted using a high using with the and to from using of plasma determined by and to be and for and depleted plasma, of of the proteins to be spiked and depleted plasma were in for and protein concentrations were to and spiked plasma with with at for and with at in the for with to at with using a to were with to a of and using to the with 3 of in with of of with of and with 2 of in were at and to plasma of were in of in and by a were at a of and with that of in and in of the the at for were with a of in in and in were and from by of to each were to the of signature peptides were using and were to peptides that by the from the and by and were from peptide derived from the target proteins were with a or using of of each peptide were by upon using protein the proteins were with and by mass with of using to peptide protein were upon the high and to the of the plasma proteins. or with or at the or and to plasma proteins. and peptide were in peptide of 2 upon were in and for were to with to plasma were in of and depleted and depleted with peptides at of were in of and of from each with of peptides at of of in were by a mass using with and in were at with in with of and with a of in 3 in and in 3 with of of of and of and were optimized for and of each with of each peptide and the in and were for each of for of plasma a of for plasma and a of to six were peptide were and at in the and and to were in using development from of the and optimized for the were in the of plasma in for each peptide using the of the with for the and peptides in plasma by for each from the in of the to be the of with a that the mass of and for each for in the to by at the by and for and are upon of and the the level in the in the of spiked proteins. by were or by the with one peptide derived from were the at in and plasma using the with were in a the to and the were the using were and using with of with and of mass of mass of and for of to test the of plasma processing and in the limit of detection and for signature peptides of candidate biomarker proteins in we and the at the of the to and with determined processing methods that of with high reproducibility and the processing six target proteins in are in of the proteins are and in the target protein we for and in and depleted plasma. that of were below the detection limits of the ng/ml for were in plasma from a healthy donor. of high plasma proteins to of the proteins from the had a the in the addition to the of the of of plasma to and of depleted plasma, processing were plasma to of protein the and the were to by peptides were by and the were to the to by from immunoaffinity and were by the target proteins to plasma to from by peptides to proteins and signature are were the in to in a are were the in to derived from and the proteins were peptide upon in of each protein with in peptide to assays for to peptides protein to the that peptides from the protein in and from processing and of the high for in plasma. for peptides that and for peptides with by and high proteins with to spiked we to quantitative to the presence of of signature peptides. peptides six proteins were of peptides were to peptides a peptide derived from and and a peptide derived from and and for peptides were and optimized for the to unbiased biomarker discovery and the targeted, approaches here the range and of the proteins in the mass the of for are to be with of the for and the in a plasma. peptides in mass by to 2 have in a targeted, in from in the mass at of of peptides the the are the of at the level by of a or of the that the or the mass the of interest. to be a upon the detection level one to achieve for the and the of the peptides to the for development to that and from that the mass of the to the of we by a of peptide to and of the in plasma were upon and the in the the mass assays for each signature peptide were optimized for to and of the optimized for the six test proteins. of the and linearity were by curves in using peptides peptides linearity over the range. peptides the were we the for the to the of the for the and Using for the and at the high of the we determined that for each and were with with high the and the and the of for and that the at the and the be in the of were to the of to for quantitative to the of in the level of the in the be limits the of to in with spiked depleted plasma for quantitative of with for of proteins in plasma of the biomarker in serum by using protein and isotope dilution Quantitative mass multiple reaction monitoring assays for plasma we the of of plasma in using the and for of and high curves in the nanogram/milliliter range were by each test protein to and depleted plasma at and in and each in are in and in for of the proteins of quantitative for target proteins spiked and depleted of with of plasma. protein dilution the dilution 3 and for and depleted plasma, the of peptide with for in in a of with of plasma. protein dilution the dilution 3 and for and depleted plasma, the of peptide with for in 2 the calibration for the peptide derived from in of peptide to peptide determined from the of the for the and curves in depleted plasma linearity of 2 orders of magnitude for the range and are of linearity of the target proteins with the of of the for the peptide in are in and and the of the in the of and are the for peptide by ng/ml protein depleted plasma and in of the with in that from the present in to in and for in ng/ml spiked plasma that the for in depleted plasma ng/ml of measurement at and of for in and and and and depleted plasma. of and the for the for peptide of in and and the peptide by of protein that had been spiked at ng/ml depleted plasma and and depleted plasma and and in the are the of the for the peptide in depleted plasma with the in and the of the and the the for the peptide in depleted plasma spiked with ng/ml of the and to the and with in the presence of a from the plasma in of the the limit of detection for peptide in depleted plasma. for protein spiked depleted plasma ng/ml with a of and of of the to for the signature peptides derived from the target proteins in and using depleted plasma the depleted plasma the of the for target proteins were ng/ml in depleted plasma and ng/ml in depleted plasma. percent of the quantitative at the for test proteins were for of in depleted plasma and of in depleted plasma. for upon the peptide to the of in the for in depleted plasma with below for of protein the in for by dilution of and depleted plasma by and dilution were by that that of of protein for and robust quantitative the of proteins with the protein of the the of to be and Based upon were in depleted plasma. quantitative for target proteins are upon of signature peptides from we to and the that have test we calibration curves for six target proteins with of signature peptides. the of the curves with with we the signature peptides to depleted and plasma at protein concentrations to that were the of the spiked peptide and protein curves for the peptide derived from curves with the and have the and the range. were of the of the signature peptides with the of we that and reproducibility are high and to measurement in known that peptides derived from the protein have to for peptides from a protein the have to be multiple peptides protein are for development with the that at least one be a for the target protein in the the of for and we peptides from each each of signature peptides a for protein in depleted plasma the of we calibration curves at concentrations with peptides and protein and the protein and peptide calibration curves for peptides and derived from in depleted plasma. for the signature peptide of the of peptide spiked by or spiked peptide depleted each signature peptide to the and for spiked protein to depleted plasma to and peptides spiked depleted plasma for the to the the curves for the peptide are the that with peptide that to with and of the for the peptide and the peptide of of the for each peptide were determined without plasma and and and and with in depleted plasma with ng/ml and and and and ng/ml spiked and and and each the of the with each of with that without plasma, that from the of each peptide derived from upon the for each signature peptide for and for and the for each and and for the peptide in depleted plasma with that for of to the for the and of for derived from in depleted plasma. of and the for the for peptide of in and and the peptide by of protein that had been spiked at and or ng/ml and depleted plasma. and in the are and the protein and peptide curves for peptides and derived from in depleted plasma, curves by the addition of peptides the for the range of concentrations that signature peptides in the calibration curves from the of protein to are the that a either in the protein or in the of by the of protein to be the for the for biomarker discovery upon at the protein peptide level to detection of proteins of had a with of and of to of plasma to limits of quantitation and detection for a the of and for to a candidate biomarker in the to a of the that have detection and at the throughput, we a for of depleted and plasma that relies the of multiple signature peptides test we the and ng/ml spiked of plasma by the of with we the for that were to the calibration curves in plasma. the of the for the of the ng/ml spiked plasma with the of the signature peptides in the of plasma. for the signature peptides were by of the and of the plasma and were to of each plasma to of were to peptides in a and to of of the signature peptides for the target proteins that of the by to in for test proteins at or below ng/ml in plasma the calibration curves for the peptide derived from in and plasma are in plasma, concentrations upon the of to with the concentrations the range the in plasma a and with to the in plasma and from the concentrations at the of the to the presence of at the of the for the peptide to ng/ml with to ng/ml with in of quantitative for target proteins in depleted of 3 and the of depleted peptide with of 3 for plasma. in peptide derived from 2 in the in the for and determined from the and for and in a of 3 and the of depleted plasma. peptide with of 3 for plasma. in peptide derived from 2 in the in the for and determined from the and for and the of peptide for peptides. signature from the of the for the peptide in and depleted plasma. and in the at the the peptide and for the and ng/ml of in depleted plasma. the of the and the with that of the and of for the the depleted plasma, of for the in the ng/ml of with in of the with for in plasma be to the picogram/milliliter range. the high and of the peptides and in the in the in quantitative and of and we have with the signature peptide derived from of and in the plasma we were below were by addition of calibration curves for peptide the of plasma by from either exogenous protein or spiked peptide to peptide in plasma were the at high protein or peptide signature peptide from to the to with are the high percent for the peptide in plasma with to the target concentrations of spiked protein the protein for in we for of to depleted plasma, and were with target concentrations and of the peptide by the by to the one to by for peptide and the presence of in one or of we the of the of the peptide in plasma with and without the addition of exogenous protein the and peptide with a mass the mass of in the in the of a at with the for the of the for the peptide and the peptide in the from plasma spiked with ng/ml the presence of a in to a of the level of and the for detection in plasma at at or below monitoring the of multiple for have been to the presence of that present at the range we using peptide from plasma in the and we were to for with of ng/ml in plasma the of the peptide in plasma the peptide with a of the the of the the of in the in the peptide with the peptide were the using a of the the the mass that must be present at the to for the mass of the a peptide from with a the of the the from the with the and the from the the in the a isotope of the peptides to the of the are to the of the of protein at the immunoaffinity and we of the six target proteins to plasma to processing at concentrations from to ng/ml from of with to the that for the of the plasma spiked with proteins at ng/ml for and the were depleted and were determined by of the signature peptides and for at the signature peptides be protein at the protein calibration curves were for the proteins to of the plasma, and were by and by percent protein upon the of the proteins of at protein at the were to at that the reproducibility of high and a of and the by we have determined that protein at the peptide at the and from protein by of the of depleted and plasma at of for and the by by were to at to in from to for the peptides for detection and quantitation of target peptide or protein in or or by from to by of and of the or serum with to the of proteins present in the of and and the of protein plasma and the of in we have that peptides be in the to for protein in the to range of plasma by achieve detection and quantitation limits in the range for plasma of the biomarker in serum by using protein and isotope dilution Quantitative mass multiple reaction monitoring assays for plasma are for of the and mass of the mass and range of typically limit detection and in the of of to plasma processing methods that enable development of quantitative, and multiplexed MS-based assays for measurement of plasma proteins in the to range of a range in clinical biomarkers by of with a and a of serum detection limits of for protein by methods be in plasma of protein in the serum of with using multiple reaction monitoring mass and peptide the methods in that were for measurement and of the the that of plasma detection of proteins. the present we have and robust plasma processing methods and in to for and for proteins at in plasma. the we and for detection and of in quantitation of peptides in plasma. to of development to quantitative, multiplexed MS-based assays for proteins that limits of quantitation in the 1–10 ng/ml range without the of of high proteins by immunoaffinity by protein peptide to be for and detection in unbiased biomarker discovery approaches for high range of the plasma to for of the serum protein and peptide methods detection of proteins in plasma and serum of the biomarker discovery a a of the of a of each of must be by a a to using must be to a of to in a of to the methods developed for unbiased discovery are to the of the to and Quantitative mass multiple reaction monitoring assays for plasma the of the by quantitative for to high plasma proteins in a of were in plasma. Using depleted plasma a in or for peptides. have been to quantitative assays for target proteins in plasma without immunoaffinity to of the biomarker in serum by using protein and isotope dilution to proteins below in plasma. the present we have that protein with peptide by and of proteins by to with of proteins in plasma. protein we the of immunoaffinity that and from plasma. were by a of from of to ng/ml by of the proteins addition to from the of peptides that be derived from the of the plasma protein of peptide to be the for the of the the of protein in plasma from to a in the protein to a in the of are to present of protein to the in for of and in for the of interest. of proteins that upon we have that of the test proteins are in and are with in of protein biomarkers we have the of to proteins and and using by and of each protein upon and that the enrichment for proteins and in the in the of to were by peptide by immunoaffinity for of the target proteins were determined to be at least the percent of the assays were 15% and were Based upon the for the signature the for protein be the picogram/milliliter level in plasma, that to biomarkers by in range without processing and methods in level of to at or or of from the or assays we for proteins stable isotope dilution of peptides in for the peptides with quantitation of either the peptide or the protein the in the processing are or percent for the determined protein concentrations the target proteins from to Sample be and by the range of to for peptide derived from the target proteins in of protein at the of processing be to for of protein or in the of peptide Quantitative mass multiple reaction monitoring assays for plasma in using proteins of signature be for and of the protein to the of protein the of assays for measurement of in or the we have of protein at the and for peptides at the the are by the in and the high of the in peptide or in in the are the of the in to be to the for addition we are at the peptide and at for in a using of for of plasma depleted of for mass of of that be for the by the and the with the of a the the of that be the of the of for the each a of the of signature and of the signature peptide be in each the of signature peptides to the of the for the peptides of to the to lists of for of the the of that be a a or the approaches be in a and in of in for a of the mass and be in to and Using the processing and each each of in by the of for to signature peptides the of peptide and for candidate biomarkers and be to and methods have been to to and for of the plasma of proteins or peptides been to plasma and enable detection of proteins and mass to and of using stable isotope and mass quantitative of serum proteins using and mass coupled with mass for detection of plasma proteins by multiple reaction monitoring of be peptides from plasma proteins were in of serum and of using stable isotope and mass quantitative of serum proteins using and mass are that the peptides be for development and that in the level of peptide either a of a in the level of at or a in the level of the be immunoaffinity of peptides with stable isotope dilution a for of assays for proteins in plasma to quantitation of peptides and proteins using stable isotope and by the of are to be that a enrichment be for proteins in plasma using enrichment of peptides for of serum that coupled to the approaches here the development of quantitative MS-based assays for proteins present at picogram/milliliter in in development to the peptides of signature we upon of of quantitative for six target proteins with in and depleted plasma. were for peptides derived from the test in each signature peptide the and have that multiple peptides derived from the target protein have of protein in the serum of with using multiple reaction monitoring mass and peptide of quantitative in clinical have to the and multiple with to the for the peptides. of multiple signature peptides target protein the that a and be methods for peptides from proteins that are to be in are for of the peptides for each protein in to be of peptides for quantitative for detection and quantitation by by the serum a protein with a range in protein presence of peptides derived from proteins of interest. from are by of and the of the plasma and the of that from peptides the mass of the mass a peptide been for peptide quantitation in of proteins and from by are to using one peptide the be a of either the the of or we have here for using to for peptides in be and in detection of the presence the level of a peptide that be from the of interest. we have one the of multiple for the peptide to of the presence of in and enable quantitation using in or Based the quantitative assays that processing be and for plasma proteins in the 1–10 ng/ml range with that for and methods that are in methods and the and of by in assays for proteins in Using the approaches we have quantitative assays for proteins biomarkers of in and are using methods to proteins at nanogram/milliliter in and of protein biomarkers of in by in of the and to be are of peptide immunoaffinity enrichment with the of the range of the to in a for of candidate biomarkers in plasma. and from the at the of for the and of the peptides and from for of protein and peptide and from and for in the for and from for from the and and from for with